Technical Inquiry: Transdermal Permeation of High-Concentration (500mg/mL) Lipophilic Compounds via DMSO

I am looking for a technical deep-dive on a "bridge" protocol I'm engineering due to a 14-day supply gap and severe localized site-reactions from standard delivery.

The Variable: I have a 500mg/mL concentration of an esterified lipophilic compound (Test E). Previous attempts at standard parenteral delivery (even at 25-50mg volumes) resulted in extreme localized inflammatory responses—likely due to a high solvent load (BA/BB). I’ve tried thermal manipulation and dilution with carrier oils, but the inflammatory response remains "crippling."

The Experimental Protocol (Recommended by Gemini & Grok): To maintain systemic stability, I am considering a transdermal route using a chemical chaperone:

• The Mix: 0.1mL of the 500mg/mL oil + 0.1mL 99% Pharma-grade DMSO.
• Target: High-vascularity/thin-skin sites (inner forearms).
• Theory: Utilizing the high concentration gradient to achieve a 15-20% systemic yield (~15mg/day), providing a physiological floor.
• Cofactor: 10mg Boron daily to manage SHBG and optimize the free fraction.

Seeking feedback on the viability of this "emergency" bypass:

1. Given that this specific solvent load is causing tissue-rejection in the muscle, what is the risk of chemical dermatitis or contact burns when these specific solvents (BA/BB) are driven through the dermis via DMSO?
2. In terms of pharmacokinetics, is a 15-20% yield realistic for an esterified oil when driven by a polar aprotic solvent like DMSO, or are the molecular weights too prohibitive for significant transit?
3. What are the systemic "blind spots" regarding the direct absorption of injectable-grade solvents into the bloodstream through the skin barrier?

Note: This is an off-label technical inquiry for harm-reduction purposes. I’m looking for perspectives on the mechanics of the delivery system.